Thiel-backed Compass adds $49M to A round, bringing total to $132M
A Cambridge startup that’s been trying — and failing — to operate under the radar these past three years is now ready to step into the limelight. Compass Therapeutics says it’s finally wrapped its years-long quest to raise a Series A mega-round totaling $132 million, and it’s heading to the clinic with a lead immuno-oncology drug.
The company has been collecting chunks of money for this raise over the past three years, with word leaking rather early in the fundraising process. Reporters have dug up fundraising updates several times since (including a piece noting Peter Thiel was a backer), shedding some light on the company before it was quite ready, Compass CEO Tom Schuetz tells me.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.